A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

Summary

The purpose of this study is to look at the effects of RN624 on moderate to severe knee pain due to osteoarthritis. This study will look at the safety and pain relieving effects of RN624 compared to placebo over a 4 month period.

Timeline

Start

2006-03

Primary completion

2007-10

Completion

2007-10

Outcome

Met primary endpoint

paper ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P<0.001). PMID 20942668 ↗

Publications

• Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010 Oct 14;363(16):1521-31. doi: 10.1056/NEJMoa0901510. Epub 2010 Sep 29.

Drugs

Indications